Stavanger UncomPlicatEd Elective PCI Same DaY Discharge Study (SPEEDY Study)

NCT ID: NCT02513108

Last Updated: 2019-05-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

82 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-12-31

Study Completion Date

2018-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to provide information on safety of same day discharge after uncomplicated percutaneous intervention (PCI) for stable angina pectoris in Norwegian clinical practice. The investigators also think that is in patients interest to stay as short time as possible in hospital and this will be measured using standardised quality of life questionnaires.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The international literature has already provided documentation on the safety of same day discharge in various clinical scenario. In this particular study, the investigators focus on challenging the contemporary Norwegian practice where every body stays over night.

Only patients with stable angina pectoris will be included in the study. After informed consent and successful procedure, the patients will be randomised to same day discharge or standard care. Same day discharge patients will be contacted by telephone the day after the procedure for follow-up conversation with particular emphasis on access site complications.

Both groups will receive quality of life questionnaire within a month for assessment of difference between the two strategies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

original sample size calculation is amended from 151 patients to 82 patients after recalculation

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

same day discharge

patients discharged same day after uncomplicated PCI

Group Type ACTIVE_COMPARATOR

same day discharge

Intervention Type PROCEDURE

same day discharge after PCI for stable CAD

standard care

standard care where patients are discharged the day after procedure after adequate observation

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

same day discharge

same day discharge after PCI for stable CAD

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Elective procedures Monday through Thursday
* Patient consenting for same day discharge
* Operator has assessed the patient and is in agreement
* Adequate observational facility
* Uncomplicated procedure
* Acceptable social network at home
* Uneventful post PCI ECG
* Adequate hemostasis of puncture site

Exclusion Criteria

* Angiographic

* No-reflow/slow flow post PCI
* Sub-optimal PCI result
* Dissection type C-E
* Rest dissection after stent deployment
* Angiographic thrombus
* Guidewire perforation
* Clinical

* Advanced age
* Severe renal failure (GFR \< 30ml/min)
* Excessive bleeding risk
* Symptomatic heart failure
* Severe visual or hearing impairment
* Multi-vessel PCI (2 main vessels or left main)
* Use of GP IIb/IIIa inhibitors
* Social

* Living alone or has no telephone
* Long driving distance (\> 30-45 min)
* Patient/next to keen can“t communicate with health personnel without a translator
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Helse Stavanger HF

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nigussie Bogale, M.D, PhD

Role: PRINCIPAL_INVESTIGATOR

Helse Stavanger HF

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Stavanger University Hospital

Stavanger, Rogaland, Norway

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Norway

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SUS2015NIBO01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Resistance STEMI Study
NCT03439150 TERMINATED NA